Sunman, regarding the nonsense that surrounded the ticker IBRX, it seems a small handful of posters, or one with multiple aliases was running a pump and dump - not very effectively, but that's how it seemed. I don't know if it's a good or mediocre play, but I do know the comparisons that were being made by that small group of noise makers are blatant lies and misinformation. Many of the posters on that board have also grown tired of that incessant nonsense as it didn't help in having a true and detailed conversation about their investment in that company. I use message boards to encourage me to dig a little deeper when I hear something that raises a question or a point of value.
Agreed, it's only noise and nonsense, but I assume it did and does have an effect on some retail investors. Hey, it got me to look if only briefly, but that's what I require of myself to know that I'm doing my due diligence on IOVA.
I've done my due diligence and I have high confidence in my IOVA investment. Amtagvi has the potential to get Iovance into the black by the end of next year (a "blockbuster" therapy of sorts) because of the team at Iovance that's bringing it to market. I do not own any of that other company, but I can't say if it should or should not be considered.
Like I said before, an approved drug or therapy is only part of the equation, even if it has potential of blockbuster status, getting it to market and prescribed by the medical community is "a whole nother thing" (my idiom for today).
Good luck to the Iovance investors, it would seem we have a blockbuster therapy and a winning team running the company.
